Skip to main content
Clinical Trials/CTRI/2025/04/085721
CTRI/2025/04/085721RecruitingNot Applicable

A prospective, randomized, double blind, two arm, comparative clinical study to evaluate the safety and efficacy of Nixoderm tube in tinea corporis infection in adult subjects.

MsSC Johnson Son Nigeria Ltd1 site in 1 country40 target enrollmentStarted: December 5, 2025Last updated:

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
40
Locations
1
Primary Endpoint
1. Percentage reduction in ringworm infection from baseline to all

Study Overview

Brief Summary

Tinea corporis is a superficial fungal skin infection of the body caused by dermatophytes. Tinea corporis is present worldwide. It is defined explicitly by the location of the lesions that may involve the trunk, neck, arms, and legs. Alternative names exist for dermatophyte infections that affect the other areas of the body. These include the scalp (tinea capitis), the face (tinea faciei), hands (tinea manuum), the groin (tinea cruris), and feet (tinea pedis). The dermatophyte’s ability to attach to the keratinized tissue of skin forms the basis for the dermatophytoses (superficial fungal skin infections). The dermatophytes causing tinea corporis belong to genera Trichophyton, Epidermophyton, and Microsporum. Trichophyton rubrum is the most common species to cause dermatophyte infections in the last 70 years. T. Rubrum accounts for 80 to 90% of the strains. Other common isolates include Trichophyton mentagrophytes and Microsporum audouinii. Infection typically occurs with direct contact with the skin from the soil, animals, or the skin of other humans. 1,2 Tinea corporis is exceedingly common worldwide. Dermatophytes are the most prevalent agents of superficial fungal infections. Excessive heat, high relative  humidity, and fitted clothing have correlations to more severe and frequent disease.3 The lifetime risk of acquiring tinea corporis is estimated to be 10–20%. Tinea corporis occurs most frequently in post-pubertal children and young adults

Study Design

Study Type
Interventional
Allocation
Computer generated randomization
Masking
Double Blind Double Dummy

Eligibility Criteria

Ages
18.00 Year(s) to 65.00 Year(s) (—)
Sex
All

Inclusion Criteria

  • Male and Female participants
  • Aged between 18-65 years.
  • Diagnosed with tenia corporis infection
  • Willing to give Informed Consent.
  • Willing to complete the study assessments/questionnaires.
  • Willing to avoid usage of his/her own skin care products in controlling tenia corporis infection for at least one week before the commencement and during this study.

Exclusion Criteria

  • Pregnancy or breast feeding.
  • Participants with the history of hypersensitivity to skin care products.
  • Participants with mild to severe anaphylaxis reaction.
  • Participants with pre-existing severe systemic disease necessitating long term medication.
  • Participants with any other concomitant skin diseases such as psoriasis, eczema etc
  • Evidence of significant uncontrolled co-morbid disease which in the investigators opinion would jeopardize patient participation.
  • History of cancer, including solid tumors, hematologic malignancies and carcinoma in situ.
  • Participation in the current or previous clinical trial with any approved or investigational products during the past 1 month.

Outcomes

Primary Outcomes

1. Percentage reduction in ringworm infection from baseline to all

Time Frame: Screening, Day 15, and Day 30

study visits to be evaluated by following parameters:

Time Frame: Screening, Day 15, and Day 30

1.KOH preparation of fungus

Time Frame: Screening, Day 15, and Day 30

2.Dermatological Assessments

Time Frame: Screening, Day 15, and Day 30

3.Percentage reduction in itching and scaling from baseline to all

Time Frame: Screening, Day 15, and Day 30

study visits by Visual Analogue Scores.

Time Frame: Screening, Day 15, and Day 30

Secondary Outcomes

  • The safety of Nixoderm tube in tenia corporis infection from(baseline to all study visits is determined by evaluating adverse events)

Investigators

Sponsor
MsSC Johnson Son Nigeria Ltd
Sponsor Class
Other [[Cosmetic Industry]]

Study Sites (1)

Loading locations...

Similar Trials